Ignyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company's pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:RXDX
- CUSIP: N/A
- Web: www.ignyta.com
- Market Cap: $598.66 million
- Outstanding Shares: 41,836,000
- 50 Day Moving Avg: $7.49
- 200 Day Moving Avg: $7.30
- 52 Week Range: $4.15 - $10.60
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.32
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.39 per share
- Price / Book: 7.30
- EBIDTA: ($111,870,000.00)
- Return on Equity: -113.19%
- Return on Assets: -71.37%
- Debt-to-Equity Ratio: 0.51%
- Current Ratio: 5.14%
- Quick Ratio: 5.14%
- Average Volume: 705,498 shs.
- Beta: 2.14
- Short Ratio: 0.85
Frequently Asked Questions for Ignyta (NASDAQ:RXDX)
What is Ignyta's stock symbol?
Ignyta trades on the NASDAQ under the ticker symbol "RXDX."
How were Ignyta's earnings last quarter?
Ignyta, Inc. (NASDAQ:RXDX) announced its quarterly earnings results on Monday, May, 1st. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.69) by $0.27. View Ignyta's Earnings History.
Where is Ignyta's stock going? Where will Ignyta's stock price be in 2017?
4 analysts have issued 1-year target prices for Ignyta's shares. Their predictions range from $15.00 to $27.00. On average, they expect Ignyta's share price to reach $20.67 in the next year. View Analyst Ratings for Ignyta.
What are analysts saying about Ignyta stock?
Here are some recent quotes from research analysts about Ignyta stock:
- 1. According to Zacks Investment Research, "Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. " (5/30/2017)
- 2. Cantor Fitzgerald analysts commented, "Entrectinib in ROS1 Shows Strong Interim Data. RXDX reported interim data in 32 patients with ROS1 NSCLC from the Phase II STARTRK2 trial, with an ORR of 75% (24/32 patients) as of a 12/16 cutoff, with a median duration of treatment of 17.2 months (PFS of 19.1 months, 63% of patients still on study). Looks Competitive. There are other agents for ROS1 NSCLC, but we think entrectinib is a competitive contender among the ROS1 agents. Of note are across-the-board positive ORR and DOR in both TKI-naive patients with and without CNS metastases: 34% of the patients in the dataset had CNS lesions, and responses were observed in 7/11, an ORR of 64%. NDA Strategy, Top Line Data in 2018. In addition to the data release RXDX confirmed the filing strategy that will see two separate NDAs for ROS1 NSCLC and a potential molecular defined label (rather than tumor-specific) label for TRK alterations. We anticipate the completion of enrollment of both ROS1 and TRK arms in 3Q17, with top line data in 1H18 and NDA filings in that year. Clear Strategy, Other Assets. With FDA confirmed regulatory plans in hand, we think the definitive NDA roadmap for entrectinib is a positive for the shares. We also believe that pipeline updates for RXDX-105, a BRAF/EGFR/RET inhibitor in Phase Ib, and RXDX-106, a Tyro-3/Axl/Mer (TAM) inhibitor in Phase I, could also be valuation drivers for the shares. Valuation and EPS. We have updated our model and are introducing our 2017 quarterly EPS forecasts." (4/28/2017)
- 3. Jefferies Group LLC analysts commented, "ENA preclinical posters on RXDX-106 showed encouraging activity in both immuno-oncologic modulation and direct tumor targeting. These initial data support further development of ‘106 and we would look for more details at Dec 1 conference call. Incremental preclinical data of ‘105 and entrectinib were also presented." (11/30/2016)
Are investors shorting Ignyta?
Ignyta saw a increase in short interest in the month of June. As of June 15th, there was short interest totalling 2,207,239 shares, an increase of 167.4% from the May 31st total of 825,291 shares. Based on an average daily volume of 892,674 shares, the short-interest ratio is presently 2.5 days. Currently, 4.7% of the shares of the company are short sold.
Who are some of Ignyta's key competitors?
Some companies that are related to Ignyta include Acceleron Pharma (XLRN), Insmed (INSM), Omeros Corporation (OMER), Forward Pharma A/S (FWP), Synergy Pharmaceuticals (SGYP), Clinigen Group PLC (CLIN), Insys Therapeutics (INSY), Alder BioPharmaceuticals (ALDR), Amarin Corporation PLC (AMRN), Xencor (XNCR), Achaogen (AKAO), Five Prime Therapeutics (FPRX), Acorda Therapeutics (ACOR), Ascendis Pharma A/S (ASND), Epizyme (EPZM), Coherus BioSciences (CHRS), Revance Therapeutics (RVNC) and ZIOPHARM Oncology (ZIOP).
Who are Ignyta's key executives?
Ignyta's management team includes the folowing people:
- Jonathan E. Lim M.D., Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Jacob M. Chacko M.D., Chief Financial Officer
- Zachary Hornby, Chief Operating Officer
- Valerie Harding Start Ph.D., Senior Vice President - Chemistry, Manufacturing, and Controls
- Christian V. Kuhlen M.D. Esq., General Counsel, Secretary
- William R. McCarthy, Chief Business Officer
- Pratik S. Multani M.D., Chief Medical Officer
- James A. Bristol Ph.D., Independent Director
- Alexander W. Casdin, Independent Director
- Heinrich Dreismann Ph.D., Independent Director
Who owns Ignyta stock?
Ignyta's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (9.50%), Victory Capital Management Inc. (6.73%), Broadfin Capital LLC (6.30%), Vanguard Group Inc. (2.95%), RA Capital Management LLC (2.45%) and Frazier Management LLC (2.33%). Company insiders that own Ignyta stock include Alexander W Casdin, City Hill Venture Partners I,, Jacob Chacko, James A Bristol, James L Freddo and Jonathan E Lim. View Institutional Ownership Trends for Ignyta.
Who sold Ignyta stock? Who is selling Ignyta stock?
Ignyta's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Nationwide Fund Advisors, Bank of New York Mellon Corp and Morgan Stanley. View Insider Buying and Selling for Ignyta.
Who bought Ignyta stock? Who is buying Ignyta stock?
Ignyta's stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Victory Capital Management Inc., Broadfin Capital LLC, Nexthera Capital LP, EAM Investors LLC, Vanguard Group Inc., Neuberger Berman Group LLC and Citadel Advisors LLC. Company insiders that have bought Ignyta stock in the last two years include Alexander W Casdin, City Hill Venture Partners I,, Jacob Chacko, James A Bristol, James L Freddo and Jonathan E Lim. View Insider Buying and Selling for Ignyta.
How do I buy Ignyta stock?
Shares of Ignyta can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ignyta's stock price today?
MarketBeat Community Rating for Ignyta (NASDAQ RXDX)MarketBeat's community ratings are surveys of what our community members think about Ignyta and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Ignyta stock can currently be purchased for approximately $10.15.
Earnings History for Ignyta (NASDAQ:RXDX)Earnings History by Quarter for Ignyta (NASDAQ RXDX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Ignyta (NASDAQ:RXDX)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Ignyta (NASDAQ:RXDX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ignyta (NASDAQ:RXDX)
Insider Ownership Percentage: 15.10%Insider Trades by Quarter for Ignyta (NASDAQ:RXDX)
Institutional Ownership Percentage: 47.79%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/15/2016||James A Bristol||Director||Buy||5,000||$5.65||$28,250.00|| |
|5/4/2016||Alexander W Casdin||Director||Buy||232,000||$6.25||$1,450,000.00|| |
|3/17/2016||Jacob Chacko||CFO||Buy||10,000||$5.64||$56,400.00|| |
|3/17/2016||James L Freddo||Director||Buy||3,000||$5.39||$16,170.00|| |
|3/17/2016||Jonathan E Lim||CEO||Buy||24,852||$5.51||$136,934.52|| |
|12/16/2015||Jacob Chacko||CFO||Buy||1,500||$12.00||$18,000.00|| |
|8/20/2015||City Hill Venture Partners I,||major shareholder||Buy||8,480||$12.90||$109,392.00|| |
|6/15/2015||Robert Wild||VP||Buy||1,200||$16.35||$19,620.00|| |
|3/20/2015||Jonathan E Lim||CEO||Buy||20,000||$9.01||$180,200.00|| |
|3/17/2015||Alexander W Casdin||Director||Buy||408,750||$10.00||$4,087,500.00|| |
|11/24/2014||Jacob Chacko||CFO||Buy||1,598||$6.46||$10,323.08|| |
|8/19/2014||Jacob Chacko||CFO||Buy||1,840||$7.53||$13,855.20|| |
|8/15/2014||Jonathan E Lim||CEO||Buy||5,000||$7.60||$38,000.00|| |
Headline Trends for Ignyta (NASDAQ:RXDX)
Latest Headlines for Ignyta (NASDAQ:RXDX)
|Q2 2017 Earnings Forecast for Ignyta, Inc. (RXDX) Issued By Jefferies Group|
www.americanbankingnews.com - June 26 at 7:10 AM
|Ignyta, Inc. (RXDX) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - June 23 at 10:38 PM
|Ignyta, Inc. (RXDX) to Post FY2021 Earnings of $2.02 Per Share, Jefferies Group Forecasts|
www.americanbankingnews.com - June 23 at 1:26 PM
|UPDATE: Jefferies Assumes Ignyta, Inc (RXDX) at Buy - StreetInsider.com|
www.streetinsider.com - June 23 at 9:44 AM
|Ignyta, Inc. (RXDX) Coverage Initiated by Analysts at Jefferies Group LLC|
www.americanbankingnews.com - June 22 at 11:02 AM
|Ignyta, Inc. (RXDX) Expected to Post Earnings of -$0.52 Per Share|
www.americanbankingnews.com - June 19 at 10:26 PM
|Ignyta, Inc. (RXDX) Upgraded to Hold at ValuEngine|
www.americanbankingnews.com - June 15 at 8:10 PM
|Cantor Fitzgerald Reiterates $15.00 Price Target for Ignyta Inc (RXDX)|
www.americanbankingnews.com - June 5 at 8:42 PM
|Ignyta to Present at Jefferies 2017 Global Healthcare Conference|
finance.yahoo.com - June 1 at 8:20 AM
|Ignyta Inc (RXDX) Upgraded to "Hold" by Zacks Investment Research|
www.americanbankingnews.com - May 30 at 9:32 PM
|Ignyta Inc (RXDX) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - May 29 at 8:50 PM
|Ignyta Inc (RXDX) Cut to Sell at Zacks Investment Research|
www.americanbankingnews.com - May 27 at 8:16 PM
|Ignyta Inc (RXDX) Sees Large Increase in Short Interest|
www.americanbankingnews.com - May 27 at 8:58 AM
|Ignyta (RXDX) Granted FDA Breakthrough Therapy Designation for Entrectinib|
www.streetinsider.com - May 15 at 6:52 PM
|Cantor Fitzgerald Analysts Give Ignyta Inc (RXDX) a $15.00 Price Target|
www.americanbankingnews.com - May 15 at 3:14 PM
|Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration|
finance.yahoo.com - May 15 at 9:32 AM
|Research Analysts Issue Forecasts for Ignyta Inc's FY2017 Earnings (RXDX)|
www.americanbankingnews.com - May 11 at 10:52 AM
|Ignyta Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares|
finance.yahoo.com - May 9 at 7:09 PM
|Ignyta (RXDX) Prices 12.5M Common Stock Offering at $6.15/Share|
www.streetinsider.com - May 4 at 8:58 AM
|Ignyta Announces Pricing of Public Offering of Common Stock|
finance.yahoo.com - May 4 at 8:57 AM
|Ignyta, Inc (RXDX) PT Lowered to $15 at Cantor Fitzgerald Following News of Equity Offering|
www.streetinsider.com - May 4 at 12:20 AM
|Ignyta (RXDX) Plans 10M Share Offering of Common Stock|
www.streetinsider.com - May 3 at 7:19 PM
|Here's Why Ignyta Dropped as Much as 19.9% Today|
finance.yahoo.com - May 3 at 7:19 PM
|Somewhat Positive News Coverage Very Unlikely to Affect Ignyta (RXDX) Share Price|
www.americanbankingnews.com - May 3 at 1:02 AM
|Here's Why Ignyta Shares Dropped as Much as 21.9% Today|
finance.yahoo.com - May 2 at 5:28 PM
|Ignyta Announces Proposed Public Offering of Common Stock|
finance.yahoo.com - May 2 at 5:28 PM
|Ignyta Inc (RXDX) Issues Earnings Results, Misses Estimates By $0.27 EPS|
www.americanbankingnews.com - May 2 at 12:30 PM
|Ignyta Inc (RXDX) Expected to Announce Earnings of -$0.70 Per Share|
www.americanbankingnews.com - May 1 at 7:44 PM
|Ignyta Announces First Quarter 2017 Company Highlights and Financial Results|
finance.yahoo.com - May 1 at 6:55 PM
|Ignyta reports 1Q loss|
marketbeat.com - May 1 at 6:04 PM
|Ignyta Inc (RXDX) Given "Buy" Rating at Cantor Fitzgerald|
www.americanbankingnews.com - April 30 at 10:30 AM
|Ignyta (RXDX) Given Media Sentiment Rating of 0.33|
www.americanbankingnews.com - April 29 at 8:29 PM
|After-Hours Stock Movers 04/27: (WDC) (GOOGL) (AMZN) Higher; (ATHN) (CLD) (SBUX) Lower (more...)|
www.streetinsider.com - April 28 at 9:17 PM
|Ignyta Updates Progress towards Entrectinib Dual TRK and ROS1 NDA Submissions|
finance.yahoo.com - April 27 at 8:05 PM
|Somewhat Favorable News Coverage Somewhat Likely to Affect Ignyta (RXDX) Share Price|
www.americanbankingnews.com - April 27 at 12:06 AM
|Ignyta to Host Conference Call and Webcast Update on Entrectinib Program and STARTRK-2 on April 27, 2017|
finance.yahoo.com - April 24 at 6:06 PM
|Ignyta (RXDX) Receives Daily News Sentiment Rating of 0.28|
www.americanbankingnews.com - April 22 at 3:34 PM
|Positive Media Coverage Somewhat Likely to Impact Ignyta (RXDX) Stock Price|
www.americanbankingnews.com - April 19 at 11:17 AM
|Somewhat Positive Media Coverage Unlikely to Effect Ignyta (RXDX) Share Price|
www.americanbankingnews.com - April 14 at 10:23 PM
|Ignyta Announces New Data Highlighting Broad Potential of Both RXDX-106 and Entrectinib at the 2017 AACR Annual Meeting|
finance.yahoo.com - April 7 at 12:25 PM
|Ignyta Inc (RXDX) Given Average Rating of "Buy" by Analysts|
www.americanbankingnews.com - April 5 at 4:57 PM
|Ignyta Announces Peer-Reviewed Publication of Activity of a TRK Inhibitor in a Primary Brain Tumor: Successful Treatment of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published in Precision Oncology|
us.rd.yahoo.com - March 30 at 7:53 PM
|Ignyta (RXDX) Announces Multiple Presentations at AACR|
www.streetinsider.com - March 29 at 12:32 AM
|Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting|
us.rd.yahoo.com - March 28 at 7:31 PM
|Ignyta Inc (RXDX) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - March 25 at 7:23 AM
|Pre-Open Movers 03/24: (HTGM) (SEAS) (MU) Higher; (XENE) (FINL) (GME) Lower (more...)|
www.streetinsider.com - March 24 at 7:27 PM
|4:00 pm Ignyta is exploring strategic options for taladegib and has entered into an amended and restated license, development and commercialization agreement with Eli Lilly (LLY) for the taladegib oncology |
finance.yahoo.com - March 23 at 8:07 PM
|Ignyta Announces Exploration of Strategic Options for Taladegib, Enabled by Amendment of Taladegib License Agreement with Lilly|
finance.yahoo.com - March 23 at 8:07 PM
|IGNYTA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement|
biz.yahoo.com - March 23 at 8:07 PM
|IGNYTA, INC. Financials|
finance.yahoo.com - March 18 at 6:52 PM
Ignyta (RXDX) Chart for Wednesday, June, 28, 2017